Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
This article was originally published in The Pink Sheet Daily
Executive Summary
After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.